Work

Survodutide for MASH: disentangling weight-dependent from weight-independent liver effects

Year: 2026
Type: article
Abstract: Metabolic dysfunction-associated steatohepatitis (MASH) is the more rapidly progressive inflammatory-degenerative variant of metabolic dysfunction-associated steatotic liver disease (MASLD) and is closely and bi-directionally linked to metabolic dysfunction. In MASH, fibrotic progression drives much of its long-term clinical risk. A recent investigation by Noureddin and colleagues examined whether the beneficial effects of survodutide, a dual glucagon receptor/glucagon-like peptide-1 receptor (GLP-1R) agonist, on liver endpoints were mediated primarily through body-weight reduction or through weight reduction–independent mechanisms. The post hoc mediation analysis of a phase 2 MASH trial suggested that improvements in steatosis-related endpoints were largely weight reduction–dependent, whereas inflammation- and fibrosis-related endpoints appeared to be predominantly weight reduction–independent. These findings are relevant because they support the possibility that dual glucagon receptor/GLP-1R agonism may improve MASH through mechanisms extending beyond weight loss alone. However, the study remains exploratory, limited by its post hoc design, modest sample size, pooled dosing strategy, and lack of definitive mechanistic validation. Prospective, well-designed clinical and translational studies are now required to delineate the mechanisms that underpin the hepatic effects of survodutide.
Language: English
Subfield: Hepatology
Field: Medicine
Open Access status: diamond
OpenAlex ID: W7236841539
FWCI:
Cites: 29
Cited by:
Related to: 10